BTG is in the same space, biopharma liver cancer treatments, and has done much better than SRX IMHO. The SPs demonstrate the tale of two companies IMHO.
SRX has been weighed down by governance, risk and compliance issues IMHO but pls DYOR.
Too many scientists and marketeers not enough governance, risk and compliance folk IMHO, simple really, if you employ technical people, you get technical stuff that gets usurped by the sales people. No one is there to review the plays or the playbook IMHO but pls DYOR.
The queensland government and the SRX situation have a bit in common, a few years layed waste by enmity in the conflict of interest IMHO but pls DYOR. GW was gone as Palaszscuk will be gone not due to performance but due to the conflicts of Queensland Premier’s Partner Shaun, Gilman Wong and perceived failings of governance,
The question is will SRX and/ or Queensland recover or will they be bedevilled by the ghosts and sins of the past IMHO but pls DYOR?
Ann: CEO's Address to AGM, page-60
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)